Effects of Antiproteinuric Intervention on Elevated Connective Tissue Growth Factor (CTGF/CCN-2) Plasma and Urine Levels in Nondiabetic Nephropathy
Authors:
- Tri Q. NguyenTNTri Q. Nguyen
- Femke WaandersFWFemke Waanders
- Liffert VogtLVLiffert Vogt
- Marc H. HemmelderMHMarc H. Hemmelder
- Gozewijn D. LavermanGLGozewijn D. Laverman
- Roel GoldschmedingRGRoel Goldschmeding
- Gerjan NavisGNGerjan Navis
Open Access
- 1 August 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 6 (8) , 1845-1850
Abstract
Summary: Background and objectives: Connective Tissue Growth Factor (CTGF/CCN-2) is a key player in fibrosis. Plasma CTGF levels predict end-stage renal disease and mortality in diabetic chronic kidney disease (CKD), supporting roles in intra- and extrarenal fibrosis. Few data are available on CTGF in nondiabetic CKD. We investigated CTGF levels and effects of antiproteinuric interventions in nondiabetic proteinuric CKD. Design, setting, participants, & measurements: In a crossover randomized controlled trial, 33 nondiabetic CKD patients (3.2 [2.5 to 4.0] g/24 h proteinuria) were treated during 6-week periods with placebo, ARB (100 mg/d losartan), and ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide) combined with consecutively regular and low sodium diets (193 ± 62 versus 93 ± 52 mmol Na+/d). Results: CTGF was elevated in plasma (464 [387 to 556] pmol/L) and urine (205 [135 to 311] pmol/24 h) of patients compared with healthy controls (n = 21; 96 [86 to 108] pmol/L and 73 [55 to 98] pmol/24 h). Urinary CTGF was lowered by antiproteinuric intervention, in proportion to the reduction of proteinuria, with normalization during triple therapy (CTGF 99 [67 to 146] in CKD versus 73 [55 to 98] pmol/24 h in controls). In contrast, plasma CTGF was not affected. Conclusions: Urinary and plasma CTGF are elevated in nondiabetic CKD. Only urinary CTGF is normalized by antiproteinuric intervention, consistent with amelioration of tubular dysfunction. The lack of effect on plasma CTGF suggests that its driving force might be independent of proteinuria and that short-term antiproteinuric interventions are not sufficient to correct the systemic profibrotic state in CKD.Keywords
This publication has 48 references indexed in Scilit:
- Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and MicroalbuminuriaClinical Journal of the American Society of Nephrology, 2010
- Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretionAmerican Journal of Physiology-Renal Physiology, 2010
- Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosisArthritis & Rheumatism, 2010
- Projected Effect of Dietary Salt Reductions on Future Cardiovascular DiseaseNew England Journal of Medicine, 2010
- The Level of Connective Tissue Growth Factor in Sera of Patients with Hepatitis B Virus Strongly Correlates with Stage of Hepatic FibrosisViral Immunology, 2010
- Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled TrialAmerican Journal of Kidney Diseases, 2009
- Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of LosartanJournal of the American Society of Nephrology, 2008
- Connective Tissue Growth Factor and Susceptibility to Renal and Vascular Disease Risk in Type 1 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2008
- Urinary Connective Tissue Growth Factor Excretion Correlates With Clinical Markers of Renal Disease in a Large Population of Type 1 Diabetic Patients With Diabetic NephropathyDiabetes Care, 2006
- Connective Tissue Growth Factor Is a Mediator of Angiotensin II–Induced FibrosisCirculation, 2003